Trial Profile
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs ST 400 (Primary) ; Busulfan; Plerixafor
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms PRECIZN-1
- Sponsors Bioverativ
- 17 Nov 2023 Planned End Date changed from 9 Aug 2024 to 14 Jul 2025.
- 17 Nov 2023 Planned primary completion date changed from 9 Aug 2024 to 14 Jul 2025.
- 17 Nov 2023 Status changed from recruiting to active, no longer recruiting.